Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 20/20 | 0.58 |
| ▸ | PLK1 | P53350 | 4/20 | 0.58 |
| ▸ | BRDT | Q58F21 | 4/20 | 0.58 |
| ▸ | TAF1 | P21675 | 13/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17891538 | 0.93 | BRD4 (0.56) | BRD4PLK1BRDTTAF1 | |
| SCHEMBL15824985 | 0.89 | BRD4 (0.73) | BRD4PLK1BRDTTAF1 | |
| SCHEMBL15825338 | 0.89 | BRD4 (0.73) | BRD4PLK1BRDTTAF1 | |
| SCHEMBL15826631 | 0.87 | BRD4 (0.67) | BRD4PLK1BRDTTAF1 | |
| SCHEMBL15826266 | 0.87 | BRD4 (0.78) | BRD4PLK1BRDTTAF1 | |
| SCHEMBL862111 | 0.85 | PLK1 (0.77) | BRD4PLK1BRDTTAF1 | |
| SCHEMBL15826595 | 0.85 | BRD4 (0.58) | BRD4PLK1BRDTTAF1 | |
| SCHEMBL15826538 | 0.83 | BRD4 (0.50) | BRD4PLK1BRDTTAF1 | |
| SCHEMBL10065446 | 0.83 | BRD4 (0.56) | BRD4PLK1BRDTTAF1 | |
| SCHEMBL17839899 | 0.83 | BRD4 (0.79) | BRD4PLK1BRDTTAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160193206-A1 | BET-PROTEIN-INHIBITING DIHYDROPYRIDOPYRAZINONES | Bayer Pharma AG (DE) | 2016-07-07 | — | — | US | claimed |
| EP-2935260-A1 | BET-PROTEIN-INHIBITING DIHYDROPYRIDOPYRAZINONES | Bayer Pharma Aktiengesellschaft (DE) | 2015-10-28 | — | — | EP | claimed |
| WO-2014095774-A1 | BET-PROTEIN-INHIBITING DIHYDROPYRIDOPYRAZINONES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-06-26 | — | — | WO | claimed |
| US-20160193206-A1 | BET-PROTEIN-INHIBITING DIHYDROPYRIDOPYRAZINONES | Bayer Pharma AG (DE) | 2016-07-07 | — | — | US | disclosed |
| US-20160193206-A1 | BET-PROTEIN-INHIBITING DIHYDROPYRIDOPYRAZINONES | Bayer Pharma AG (DE) | 2016-07-07 | — | — | US | disclosed |
| US-20160193206-A1 | BET-PROTEIN-INHIBITING DIHYDROPYRIDOPYRAZINONES | Bayer Pharma AG (DE) | 2016-07-07 | — | — | US | disclosed |
| EP-2935260-A1 | BET-PROTEIN-INHIBITING DIHYDROPYRIDOPYRAZINONES | Bayer Pharma Aktiengesellschaft (DE) | 2015-10-28 | — | — | EP | disclosed |
| WO-2014095774-A1 | BET-PROTEIN-INHIBITING DIHYDROPYRIDOPYRAZINONES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160193206-A1 | BET-PROTEIN-INHIBITING DIHYDROPYRIDOPYRAZINONES | BRD4, BET1, BRDT | BRD4 1/4885PLK1 793/4885BRDT 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.